Silence Therapeutics (SLN) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$21.0 million.
- Silence Therapeutics' Income towards Parent Company rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 15.29%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
- Silence Therapeutics' Income towards Parent Company amounted to -$21.0 million in Q3 2025, which was up 23.38% from -$27.4 million recorded in Q2 2025.
- Silence Therapeutics' Income towards Parent Company's 5-year high stood at $12.3 million during Q4 2024, with a 5-year trough of -$35.5 million in Q3 2024.
- In the last 3 years, Silence Therapeutics' Income towards Parent Company had a median value of -$18.6 million in 2023 and averaged -$16.8 million.
- As far as peak fluctuations go, Silence Therapeutics' Income towards Parent Company skyrocketed by 166.23% in 2024, and later plummeted by 1,134.00% in 2025.
- Over the past 5 years, Silence Therapeutics' Income towards Parent Company (Quarterly) stood at -$15.1 million in 2021, then fell by 16.64% to -$17.7 million in 2022, then dropped by 5.23% to -$18.6 million in 2023, then spiked by 166.23% to $12.3 million in 2024, then surged by 41.04% to -$21.0 million in 2025.
- Its Income towards Parent Company stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.